- Home
- TCBI vs ARQT Comparison
TCBI vs ARQT Comparison
Compare TCBI & ARQT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | TCBI | ARQT |
|---|---|---|
| Founded | 1996 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.9B | 3.3B |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | TCBI | ARQT |
|---|---|---|
| Price | $100.57 | $20.66 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 13 | 6 |
| Target Price | ★ $100.92 | $34.00 |
| AVG Volume (30 Days) | 390.5K | ★ 916.6K |
| Earning Date | 04-23-2026 | 05-06-2026 |
| Dividend Yield | ★ 0.81% | N/A |
| EPS Growth | N/A | ★ 88.79 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $376,072,000.00 |
| Revenue This Year | $14.76 | $34.85 |
| Revenue Next Year | $7.47 | $29.39 |
| P/E Ratio | $15.46 | ★ N/A |
| Revenue Growth | N/A | ★ 91.34 |
| 52 Week Low | $70.00 | $12.72 |
| 52 Week High | $108.92 | $31.77 |
Technical Indicators
Market Signals| Indicator | TCBI | ARQT |
|---|---|---|
| Relative Strength Index (RSI) | 50.69 | 32.22 |
| Support Level | $81.58 | $19.60 |
| Resistance Level | $106.94 | $21.84 |
| Average True Range (ATR) | 2.95 | 1.09 |
| MACD | -0.32 | -0.18 |
| Stochastic Oscillator | 39.00 | 3.08 |
Price Performance
Historical ComparisonAbout TCBI Texas Capital Bancshares Inc.
Texas Capital Bancshares Inc is a registered bank holding company and a full-service financial services firm that delivers customised solutions to businesses, entrepreneurs and individual customers. It is a secured lender with the majority of the loans held for investment, excluding mortgage finance loans and other national lines of business. Texas Capital has established commercial banking, consumer banking, investment banking and wealth management capabilities.
About ARQT Arcutis Biotherapeutics Inc.
Arcutis Biotherapeutics Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing treatments for dermatological diseases with high unmet medical needs. Its current portfolio is comprised of differentiated topical and systemic treatments with potential to treat immune-mediated dermatological diseases and conditions. The company's product candidate ZORYVE roflumilast cream, has completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population. The Company has one reportable segment relating to the development and commercialization of treatments for dermatological diseases.